Immuneering Announces First Patient Dosed in Pivotal Phase 3 MAPKeeper 301 Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer
Immuneering has dosed the first patient in MAPKeeper 301, a pivotal Phase 3 trial evaluating atebimetinib plus modified gemcitabine/nab-paclitaxel in first-line metastatic pancreatic cancer. The global, randomized study compares the combination therapy against standard GnP alone, with overall survival as the primary endpoint.
Key figures
- Drug Name
- atebimetinib
- Phase Of Trial
- Phase 3
- Trial name
- MAPKeeper 301
- Primary endpoint
- overall survival
- Topline data date
- mid-2028
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.